MedTrace Logo

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

NCT03209479 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1332

Last updated 2024-06-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of Copaxone subcutaneous injection syringe (hereinafter referred to as Copaxone) in patients with multiple sclerosis in the routine clinical setting.

Conditions

Interventions

DRUG

Glatiramer acetate

Copaxone subcutaneous injection syringe

Sponsors & Collaborators

  • Teva Takeda Pharma Ltd.

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda (Note: This product was divested to Teva Takeda Pharma Ltd. in 2024.)

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-24
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03209479 on ClinicalTrials.gov